Table 3 Growth inhibitory effect of Doxorubicin (ID50) with and without CCI-779
From: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
| Â | DOX (ug/ml) | DOX+0.01 ug CCI-779 | DOX+1 ug CCI-779 |
|---|---|---|---|
SCLCA | 0.09 ± 0.02 | 0.07 ± 0.01 | 0.08 ± 0.02 |
SCLCR | 0.042 ± 0.01 | 0.058 ± 0.02 | 0.009 ± 0.005 |